SCHEMBL1769345

SCHEMBL1769345

CCOC(=O)C1(c2ccc(NC(=O)OCc3ccccc3)cc2F)CC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
MAPT P10636 1/20 0.48
ATM Q13315 1/20 0.48
MGLL Q99685 3/20 0.47
PTGDR2 Q9Y5Y4 1/20 0.47
PTPN1 P18031 1/20 0.44
POLB P06746 1/20 0.44
ENPP2 Q13822 1/20 0.43
KDM1A O60341 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ROCK2 O75116 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6611121 0.90 RAB9A (0.45) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL6607338 0.88 SMN1; SMN2 (0.47) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL591401 0.81 MGLL (0.59) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL6610001 0.80 TP53 (0.51) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL6610098 0.77 MGLL (0.47) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL6401881 0.76 TSHR (0.47) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL30853659 0.76 MGLL (0.59) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL2088984 0.76 MGLL (0.59) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL6399505 0.76 MCHR1 (0.47) NPC1RAB9ASMN1; SMN2TSHRALDH1A1
SCHEMBL6398417 0.76 MCHR1 (0.47) NPC1RAB9ASMN1; SMN2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011061760-A1 NOVEL ANTITHROMBOTIC AGENTS CADILA HEALTHCARE LIMITED (IN) 2011-05-26 WO disclosed